Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Eosinophilic oesophagitis
- Focus Registrational; Therapeutic Use
- Acronyms EoE KIDS
- Sponsors Regeneron Pharmaceuticals
- 26 Feb 2024 Results presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 26 Feb 2024 Results assessing dupilumab efficacy on transcriptome outcomes in children, presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 26 Feb 2024 52-week results presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology